Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer

ISSN： 0262-0898

Source： Clinical and Experimental Metastasis, Vol.30, Iss.5, 2013-06, pp. : 595-606

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zoledronic acid in lung cancer with bone metastases: a review

By Isla Dolores Afonso Ruth Bosch-Barrera Joaquim Martínez Natividad

Expert Review of Anticancer Therapy, Vol. 13, Iss. 4, 2013-04 ,pp. : 421-426

Informa Healthcare

Access to resources Recommend Favorite

Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

By Song Zhengbo Zhang Yiping

Medical Oncology, Vol. 31, Iss. 4, 2014-04 ,pp. : 1-4

Humana Press, Inc

Access to resources Recommend Favorite

Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug

By Young Robin J Coleman Robert E

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 633-643

Future Medicine

Access to resources Recommend Favorite

Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro

Molecular Medicine Reports, Vol. 13, Iss. 1, 2016-01 ,pp. : 613-622

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 4, 2017-04 ,pp. : 542-551

Bentham Science Publishers

Access to resources Recommend Favorite